Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) – Advances & Applications

Description

Market Report, 381 Pages
December 2025

Mesenchymal stem cells (MSCs) are an exciting area of regenerative medicine due to their ability to differentiate, reduce inflammation and fibrosis, promote tissue repair, modulate the immune response, and produce therapeutic exosomes. Beyond their use as cellular therapeutics, MSCs are finding use within emerging applications, such as tissue engineering, organoid production, cosmeceutical development, and cultured meat production.

Today, 12 MSC-based cell therapies are available to be marketed globally. This includes 11 full approvals and a 12th conditional approval within China. Only one of these products is approved for use within the U.S., Mesoblast’s Ryoncil (remestemcel-L-rknd), which received FDA approval in December 2024. A 13th product, Takeda’s Alofisel, was approved by the European EMA in 2018, but it was voluntarily withdrawn on December 13, 2024.

The 12 globally approved MSC-based cell therapies include:

Republic of Korea:

• Queencell from Anterogen
• Cellgram AMI from Pharmicell
• Cupistem from Anterogen
• Cartistem from Medipost
• NeuroNataR from Corestem

Japan:

• Temcell HS from JCR Pharmaceuticals
• Stemirac from Nipro Corporation

Europe: 

• Holoclar from Chiesi Farmaceutici
• *Previously, Alofisel from Takeda/TiGenix was approved by the EMA, but it was withdrawn in December 2024.

India:

• Stempeucel from Stempeutics

Iran:

• MesestroCell from Cell Tech Pharmed

Canada and the U.S. have approved:

• Prochymal, also branded as Ryoncil (remestemcel-L) from Mesoblast

China has given Conditional Approval to one product:

• Ruibosheng, an umbilical cord-derived MSC product (amimestrocel injection) from Platinum Life Excellence

As a leading cell type being used within regenerative medicine, there is great potential for growth within the MSC market. Current “hotspots” for MSC clinical trials include the U.S., E.U., China, the Middle East, and South Korea. While many early-stage MSC trials have demonstrated safety and efficacy, only a small number of MSC products have reached commercialization, indicating that the therapeutic market for MSCs remains early-stage. Today, at least 17 clinical trials using MSCs have reached Phase IV, indicating that a number of MSC products have near-term market potential and the therapeutic market for MSCs looks promising.

The Market for MSCs in 2026

Today, there are at least 125 market competitors who are are developing various types of MSC-related products, services, therapies, and technologies. Within this rapidly changing landscape, having a thorough understanding of the competition, their proprietary technologies, and their strengths and weaknesses is essential.

Therefore, this global strategic report presents detailed market size figures for the Global MSC Market, segmented by Geography and Business Segment, and accompanied by future forecasts through 2031.

Objectives of this report are to provide the reader with the following details:

• Market size determination for the global MSC market, segmented by geography and business segment
• Future forecasts for the global MSC market
• MSC-based cellular therapies with marketing approval and the companies commercializing them (12 total)
• Globally marketed MSC-based bone matrices (17 total)
• Globally marketed cosmeceutical products using MSC-derived conditioned or spent medium (20 total)
• Emerging applications for MSCs, including genetic modification, 3D bioprinting, clean meat production, exosome production, and cosmeceuticals
• Details of the product candidates being developed by MSC companies
• Pricing comparison of MSC-based products with marketing approval
• MSC market trends, opportunities, risks, and competitive dynamics
• Major diseases addressed by MSCs in the ongoing clinical trials
• Opportunities and developments related to MSC-derived exosomes
• Cost of manufacturing autologous and allogeneic MSCs
• Consumption of MSCs for academic research, clinical trials, product development, and exosome production
• Trend rate data for MSC scientific publications
• Rates, types, phases, and geographic distribution of MSC clinical trials
• Rates, types, and geographic distribution of MSC patents, as well as leading inventors and sponsors
• Types and sources of MSC industry funding
• Recent business deals and developments related to MSCs
• Company profiles for 125 leading MSC market competitors, including their proprietary technologies and products/services under development
• And so much more

Proprietary Insights

As you can imagine, these market insights and the data sets upon which they are based would not be possible without the past 19+ years of following this industry and developing proprietary datasets (to which AI does not have access).

These insights exist because they are built on 19+ years of granular tracking, expert interviews, proprietary datasets, and daily monitoring of the stem cell and regenerative medicine landscape, intelligence which no AI model or generic market source can replicate.

 In a competitive market, you don’t have time to dig for answers, verify accuracy, or miss critical opportunities. If you want immediate and actionable insights from a trusted, U.S. based provider that specializes exclusively in stem cell market insights, then this report is for you.

About BioInformant

With an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with over 19 years of experience. As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal and Vogue Magazine, as well as quoted in Tony Robbin’s best-selling book, Life Force. Founded in 2006 and headquartered in Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capitol Hill. In addition to leveraging an experienced team of analysts, BioInformant has unparalleled access to key opinion leaders (KOLs) from across the stem cell sector.

To analyze the rapidly evolving stem cell sector, BioInformant conducts interviews with prominent executives from across the field. BioInformant has interviewed representatives from Cynata Therapeutics (first company to bring an iPSC-derived MSC therapeutic product into a clinical trial), RoosterBio (specializes in manufacturing tens of billions of MSCs in suspension bioreactors), Celularity, Inc. (developing MSC therapeutics from the post-partum human placenta), Pluristem Therapeutics (commercializing placenta-derived mesenchymal-like adherent stromal cells in late-stage clinical trials), BioEden/Future Health Group (leading company preserving MSCs derived from dental tissues), and Regenexx (world’s leading provider of MSC therapies for orthopedic applications).

The content within this report was compiled using a diverse range of sources, as described in this Research Methodology.

VIEW THE TABLE OF CONTENTS: Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) – Advances & Applications

Have questions? Email us at [email protected] to get a rapid reply. Checkout below to get immediate access to download this report, with printing rights allowed. To view pricing, choose a License Type from the dropdown menu below.